S 
Structure Therapeutics Inc. American Depositary Shares GPCR · USD
Health Care · US listing · 🇺🇸 United States
21.41
+5.21%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Net income
−$141.2m
FY2020FY2025
Free cash flow
−$225.8m
FY2020FY2025
Shareholders' equity
$1.52bn
FY2020FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross profit | −$3.9m | −$2.6m | −$949,174 | −$623,258 | −$266,353 | −$20,034 |
| Research and development | $225.3m | $108.8m | $70.1m | $36.2m | $29.1m | $12,364 |
| Operating income | −$287.6m | −$158.2m | −$102.8m | −$52.6m | −$37.8m | −$15,906 |
| Net income | −$141.2m | −$122.5m | −$89.6m | −$51.3m | −$40.0m | −$15,876 |
| Diluted earnings per share | -2.39 | -2.14 | -1.93 | -1.40 | -1.09 | -0.00 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Total assets | $1.58bn | $903.3m | $482.0m | $97.8m | $111.2m | $38.7m |
| Cash and short-term investments | $1.45bn | $883.5m | $467.3m | $90.8m | $107.3m | $37.4m |
| Total liabilities | $67.5m | $38.5m | $29.1m | $213.0m | $175.9m | $61.2m |
| Debt | $2.9m | $1.7m | $1.4m | $260,000 | $349,000 | $147,000 |
| Shareholders' equity | $1.52bn | $864.8m | $453.0m | −$115.1m | −$64.7m | −$22.5m |
| Shares outstanding | 59m | 57m | 46m | 37m | 37m | 37m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Cash from operations | −$222.2m | −$116.6m | −$79.5m | −$46.1m | −$32.2m | −$14.3m |
| Capital spending | −$3.6m | −$1.3m | −$2.2m | −$155,000 | −$1.2m | −$19,000 |
| Free cash flow | −$225.8m | −$117.9m | −$81.7m | −$46.3m | −$33.4m | −$14.3m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $1.8m | — |
| Gross profit | — | −$1.2m | — | — | −$853,991 | −$686,976 | $890,663 | −$267,175 |
| Operating income | −$118.6m | −$89.6m | $24.0m | −$73.8m | −$70.5m | −$56.3m | −$47.1m | −$45.8m |
| Net income | −$106.2m | −$76.2m | $33.0m | −$65.7m | −$61.7m | −$46.8m | −$36.5m | −$34.0m |
| Diluted earnings per share | -1.46 | -1.05 | 0.56 | -1.11 | -1.04 | -0.79 | -0.64 | -0.59 |
| Cash from operations | −$104.0m | $15.0m | −$64.0m | −$50.0m | −$54.0m | −$52.0m | −$36.0m | −$19.0m |
| Capital spending | −$1.0m | −$1.0m | −$1.0m | −$1.0m | — | — | — | — |
| Free cash flow | −$105.0m | $14.0m | −$65.0m | −$51.0m | — | — | — | — |
| Total assets | $1.43bn | $1.51bn | $1.58bn | $832.2m | $816.4m | $866.5m | $903.3m | $933.2m |
| Cash and short-term investments | $1.34bn | $1.46bn | $1.45bn | $799.0m | $786.5m | $836.9m | $883.5m | $915.3m |
| Debt | $2.6m | $2.6m | $2.9m | $2.8m | $2.7m | $2.5m | $1.7m | $1.7m |
| Shareholders' equity | $1.35bn | $1.45bn | $1.52bn | $770.0m | $772.1m | $824.6m | $864.8m | $896.8m |
Financial ratios
Data as of 24 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Return on equity | -9.3% | -14.2% | -19.8% | 44.6% | 61.8% | 0.1% |
| Return on assets | -8.9% | -13.6% | -18.6% | -52.5% | -36.0% | -0.0% |
| Free cash flow yield | -17.4% | -9.5% | -7.9% | -5.9% | -4.0% | — |
| Earnings growth | 15.2% | 36.7% | 74.6% | 28.3% | 251903.0% | — |
| Current ratio | 24.81x | 24.74x | 19.14x | 7.16x | 12.62x | 12.64x |
| Debt to equity | 0.00x | 0.00x | 0.00x | -0.00x | -0.01x | -0.01x |
| Equity ratio | 95.7% | 95.7% | 94.0% | -117.7% | -58.2% | -58.1% |
| Interest coverage | — | — | -5.67x | -34.26x | -308.58x | -3181.20x |
| Buybacks as a share of market value | -3.3% | -23.4% | -26.8% | 0.0% | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Operating income | 76.2% | 610.3% | — |
| Net income | 40.1% | 516.3% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Price to earnings | -29.2 | -12.7 | -21.1 |
Market value over time
28 Feb 2023 to 23 Oct 2026, in USD
$255.6m$1.54bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Return | 124% | -25% | 150% |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.